The efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) and corticosteroid therapies to treat diabetic macular edema (DME) relies on the measurement of best-corrected visual acuity (BCVA), which is considered the primary outcome in most clinical trials and in clinical settings [1,2,3,4].The assessment of retinal thickness change after treatment is based on structural optical coherence tomography (OCT) and, in particular, on the central subfield thickness (CST) measurement. Here, VEGFA is linked to diabetic macular edema.